Endocrinology

Individualized supportive interventions associated with preserved QoL and high endocrine adherence in premenopausal women

In this multicentre phase II study of 40 premenopausal women starting combination endocrine therapy, functional well‑being improved over time. Participants chose structured exercise (61%), massage (44%), acupuncture (35%), or yoga; overall endocrine‑therapy adherence was 92.5%. Emotional, social, physical, endocrine symptom, and cognitive domains remained stable, while younger age (<35) predicted worse outcomes. These findings support offering patient‑selected supportive therapies to help maintain quality of life and adherence, pending larger controlled trials. 1

Generative AI decision support did not reduce 14‑day treatment failure in Kenyan primary care

In a pragmatic cluster‑randomized trial of 9,691 primary care encounters, 14‑day treatment failure occurred in 2.2% with LLM assistance versus 2.0% with standard care. The adjusted odds ratio was 0.77 (P = 0.13), so the primary outcome did not differ significantly between arms. No serious adverse events were attributed to the intervention and independent review found no safety signal. LLM assistance was safe in this low‑resource setting but any clinical benefit, if present, is likely modest. 2

MiniMed 780G markedly increases time‑in‑range and lowers HbA1c in adults ≥65 with type 1 diabetes

In a single‑centre randomized trial in adults ≥65 years, MiniMed 780G raised median time‑in‑range from 57.4% to 79.7% at 12 months. Adjusted between‑group differences favored AHCL for TIR (15.7% increase) and HbA1c (‑5 mmol/mol), with no rise in hypoglycaemia or DKA. No serious adverse events occurred and retinal vascular status remained stable over follow‑up. The open‑label, single‑centre design limits generalizability; apply results to motivated older adults after shared decision making. 3